Fate Therapeutics
FATE
#8356
Rank
โ‚ฌ0.27 B
Marketcap
2,37ย โ‚ฌ
Share price
-0.72%
Change (1 day)
194.93%
Change (1 year)

EPS for Fate Therapeutics (FATE)

EPS in 2026 (TTM): -0,93ย โ‚ฌ

According to Fate Therapeutics 's latest financial reports the company's current EPS (TTM) is -0,94ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of -1,00ย โ‚ฌ an increase over its 2024 EPS that were of -1,42ย โ‚ฌ.

EPS history for Fate Therapeutics from 2014 to 2026

Annual EPS

Year EPS Change
2026 (TTM)-0,93ย โ‚ฌ-6.61%
2025-1,00ย โ‚ฌ-29.88%
2024-1,42ย โ‚ฌ
2022-2,52ย โ‚ฌ30.49%
2021-1,93ย โ‚ฌ7.21%
2020-1,80ย โ‚ฌ45.45%
2019-1,24ย โ‚ฌ19.17%
2018-1,04ย โ‚ฌ17.65%
2017-0,88ย โ‚ฌ-3.77%
2016-0,92ย โ‚ฌ-12.4%
2015-1,05ย โ‚ฌ-3.97%
2014-1,09ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Becton Dickinson
BDX
2,86ย โ‚ฌ-402.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-0,49ย โ‚ฌ-47.71%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
-2,02ย โ‚ฌ 113.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
5,81ย โ‚ฌ-715.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
-3,62ย โ‚ฌ 283.49%๐Ÿ‡บ๐Ÿ‡ธ USA